Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials

Abstract

Aim

This study aimed to evaluate the efficacy and safety of bimekizumab for psoriasis.

Methods

The PubMed, Web of Science, Cochrane Library, and Embase databases were systematically searched until November 20, 2022, to identify randomized controlled trials (RCTs) reporting the efficacy and safety of bimekizumab. The identified studies were screened according to inclusion and exclusion criteria, and a meta-analysis was performed on the selected studies using the Stata (version 17.0) software to investigate the efficacy and safety of bimekizumab.

Results

Six studies involving 1252 participants were considered. Compared with the control group which received placebo, the bimekizumab group had a larger number of patients with improvement in Psoriasis Area and Severity Index (PASI) of at least 75% (PASI75) (RR: 20.54, 95%CI: 12.41–33.99; p = .000), at least 90% (PASI90) (RR:16.99, 95%CI: 7.09–40.68; p = .000) and 100%(PASI100) (RR:14.57; 95%CI: 5.26–40.35; p = .000) and a larger number with improvement in Investigator Global Assessment (IGA) response (RR:22.57; 95%CI: 12.74–39.98; p = .000). There was no obvious difference between the bimekizumab and placebo groups in treatment of emergent adverse events (TEAEs) (RR:1.17; 95%CI: 0.93–1.47; p > .05) and serious TEAEs (RR: 0.67; 95%CI: 0.28–1.61; p > .05).

Conclusions

Bimekizumab shows promising efficacy for the treatment of psoriasis with favorable safety records.

Keywords:

• Psoriasis
• bimekizumab
• biologic therapy
• meta-analysis

Acknowledgments

The authors thank AiMi Academic Services (www.aimieditor.com) for English language editing and review services.

Ethics approval and consent to participate

Not applicable.

Author contribution

YY.Q. wrote the manuscript. Y.Z., YY.Q. and QL.L. extracted and analyzed the data. Y.L. and QL.L. provided professional comments to the manuscript. All authors have read and approved the final manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Additional information

Funding

The authors declare that they did not receive any funding from any source